EXHIBIT I.19

1	IN THE UNITED STATES DISTRICT COURT
	FOR THE NORTHERN DISTRICT OF OHIO
2	EASTERN DIVISION
3	EASIEIU DIVISION
	IN RE NATIONAL PRESCRIPTION
4	
4	OPIATE LITIGATION Hon. Dan A. Polster
	MDL No. 2804
5	THIS DOCUMENT APPLIES TO ALL No. 17-MD-2804
	CASES
6	/
7	
8	HIGHLY CONFIDENTIAL -
	SUBJECT TO FURTHER CONFIDENTIALITY REVIEW
9	
10	
	THURSDAY, JANUARY 10, 2019
11	
12	
	Videotaped Deposition of DONALD WALKER, held
13	at the Law Offices of COVINGTON & BURLING, One Front
	Street, 35th Floor, San Francisco, California,
14	beginning at 8:57 a.m., before Sandra Bunch
	VanderPol, FAPR, RMR, CRR, CALIFORNIA CSR #3032
1 =	ValidelPOL, FAPR, RMR, CRR, CALIFORNIA CSR #3032
15	
1	
16	
17	
18	
19	
20	
21	
22	
	GOLKOW LITIGATION SERVICES
23	877.370.3377 ph 917.591.5672 fax
	Deps@golkow.com
24	<u> </u>
25	

- 1 Regulatory Affairs Group was in there, and I had a
- 2 group that was responsible for construction and
- 3 building of our distribution centers.
- 4 Q. You mentioned Regulatory Affairs.
- 5 What kind of regulatory affairs matters were you
- 6 responsible for as Senior Vice President of
- 7 operations -- distribution operations, I should say?
- A. McKesson, and the wholesalers as an
- 9 industry, are highly regulated. We have
- 10 responsibilities for a number of regulatory
- 11 requirements. The FAA, the Department of
- 12 Transportation, DOT, OSHA. We had hazardous material
- 13 requirements. Certainly we had responsibility for
- 14 compliance with DEA regulations. And various state
- 15 and local regulations as well.
- 16 O. What was involved in the handling of
- 17 controlled substances in particular?
- 18 A. Our -- our distribution network in
- 19 handling controlled substances was complex. The
- 20 requirements under the federal code ensure -- wanted
- 21 to ensure that we had systems in place to prevent
- 22 diversion, primarily around security, as the code
- 23 spelled out.
- And so the inside of our buildings, the
- 25 controlled substances divided into two major areas.

- 1 One, in what we called the narcotics Class 2
- 2 controlled substances were stored in a vault, much
- like a bank vault, and the balance of the controlled
- 4 substances were stored in a locked and secured cage.
- 5 There was requirements for alarm. The physical --
- 6 the physical construction of both the vault and the
- 7 cage were specified under regulation.
- And, in addition, we had reporting
- 9 requirements to the DEA, the ARCOS reporting, which
- 10 was the month-end reporting of all of our sales. We
- 11 needed to reconcile all of our receipts and all of
- our sales and our inventory, along with the physical
- inventory, to ensure that we could account for each
- 14 and every one of the controlled substances that was
- in our possession that was reportable.
- We had reporting requirements on suspicious
- 17 orders. Our suspicious order reporting we called at
- 18 the time -- prior to 2008 we gave it a moniker that
- 19 said -- basically a report number called DU45, and we
- 20 provided that suspicious order reporting to the local
- 21 DEA field offices, as required.
- 22 O. And you described the DU45 report.
- What was the DU45 report exactly?
- A. The DU45 was a report that reviewed
- 25 sales of customers' purchases of controlled

- 1 suspicious orders.
- 2 You have described the Lifestyle Drug
- 3 Monitoring Program. Earlier today Mr. Kennedy asked
- 4 you a lot of questions about the next program that
- 5 McKesson developed. That was called what?
- 6 A. The Controlled Substance Monitoring
- 7 Program, or CSMP.
- 8 Q. What was the difference between the
- 9 new CSMP program that was put into place and the
- 10 LDMP, or Lifestyle Drug Monitoring Program?
- 11 A. There were a number of things that --
- 12 that were done at that time. First, the difference
- 13 specifically in the programs is we continued to use
- 14 the concept of thresholds to monitor specific orders.
- 15 The significant difference was that we created a
- 16 systemic solution to total the dose units purchased
- 17 by a given pharmacy on a given controlled
- 18 substances -- substance. And if the order that was
- 19 generated at any given time caused the pharmacy to go
- 20 above the threshold, that entire order was blocked.
- 21 The blocking of orders was a piece.
- We had -- we continued to have the
- 23 three-part review. The difference being is that the
- 24 blocked order triggered a review process, but we
- 25 still maintained a three-tiered escalation process